secwatch.observer — SEC 8-K summary
======================================

Issuer:     TherapeuticsMD, Inc. (TXMD)
CIK:        0000025743
Form:       8-K
Filed at:   2026-05-12T20:10:33+00:00
Accession:  0001213900-26-055070
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TherapeuticsMD Q1 2026 net income $103K, license revenue up 84% YoY
-------------------------------------------------------------------

- Net income from continuing operations of $103K vs net loss of $636K in Q1 2025.
- License revenue $724K, up 84% YoY, primarily from Mayne License Agreement.
- Total operating expenses $1.45M, down 13.6% from $1.67M in prior year.
- Cash and cash equivalents $8.4M as of March 31, 2026.
- Company continues to evaluate strategic alternatives including M&A or sale of assets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/25743/000121390026055070/0001213900-26-055070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/25743/000121390026055070/ea0289776-8k_therapeu.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-055070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer